Trials / Completed
CompletedNCT03875937
The Trauma INtramuscular Tranexamic Acid Clinical Trial
Pharmacokinetics of Intramuscular Tranexamic Acid in Trauma Patients: a Clinical Trial
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- London School of Hygiene and Tropical Medicine · Academic / Other
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
Intramuscular injection of tranexamic acid (TXA) would increase its use in situations where administration of intravenous drugs is difficult. The investigators aim to assess the population pharmacokinetics of intramuscular TXA in trauma patients. Primary endpoint: Serum TXA concentrations over time. Secondary endpoints: Local reactions at injection sites and adverse events
Detailed description
A prospective, open-label, multicentre, pharmacokinetic study conducted in the UK hospital. Potential eligible patients will have received a 1 gram IV dose of TXA at the scene of the injury or on arrival in hospital and a second dose is clinically indicated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tranexamic 1 gram | To be administered intramuscularly (2 injections) |
Timeline
- Start date
- 2019-09-17
- Primary completion
- 2020-02-12
- Completion
- 2020-02-12
- First posted
- 2019-03-15
- Last updated
- 2020-04-10
Locations
2 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03875937. Inclusion in this directory is not an endorsement.